As an investor, BwB is proud to see BioOrbit secure a £9.8 million (US$13.2 million) seed round - the largest to date for space manufacturing.
BioOrbit’s pioneering model uses microgravity to grow highly uniform protein crystals that enable ultra-concentrated, low-viscosity biologic drugs.
With this round, BioOrbit advances towards:
- Repeatable crystallisation in microgravity
- Scalable manufacturing capabilities in low Earth orbit
- Commercial deployment with pharmaceutical partners
Led by Dr Katie King and Dr Leonor Teles, the BioOrbit team is translating scientific innovation into transformative impact for pharma.
The round is co-led by LocalGlobe and Breega, with support from Seedcamp, Auxxo Female Catalyst Fund, Type One Ventures, 7percent Ventures and a strong network of angel investors.
Congratulations to Katie, Leonor, and the entire BioOrbit team on this major milestone that demonstrates what’s possible when groundbreaking science and the right kind of capital align.